United-Guardian

UG

Market cap $30.6M

UG reports a sharp drop in 2025 earnings as weak cosmetic sales weigh on results, despite growth in pharmaceuticals and medical lubricants.

HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025.

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

United-Guardian's Q3 earnings fall y/y on weak cosmetic sales, pressuring margins and sending UG shares down even as pharma and medical lines grow.

HAUPPAUGE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2025. Sales for the nine-month period ended September 30th decreased from $9,705,262 in 2024 to $7,583,613 in 2025 and net income decreased from $2,747,151 ($0.60 per share) to $1,456,162 ($0.32 per share). Third quarter sales decreased from $3,060,113 in 2024 to $2,264,261 in 2025 and net income decreased from $865,484 ($0.19 per share) to $268,441 ($0.06 per share).

United-Guardian's Q2 earnings fall on weak cosmetic sales, partly offset by gains in pharmaceuticals and medical lubricants, with recovery hopes ahead.

United-Guardian (UG), a specialty ingredients manufacturer known for its pharmaceutical, cosmetic, and medical lubricant products, released its second quarter fiscal 2025 results on August 8, 2025. Alongside net income (GAAP) falling to $626,826, as cosmetic ingredient sales dropped sharply in the first six months of 2025 due to distributor inventory issues.

HAUPPAUGE, N.Y., Aug. 08, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2025. Second quarter net sales decreased from $3,390,205 in 2024 to $2,838,225 in 2025, with net income decreasing from $956,225 ($0.21 per share) to $626,826 ($0.14 per share). As compared with the first quarter of 2025, the second quarter net sales increased by 14% and net income increased by 12%. Net sales for the six-month period ended June 30th decreased from $6,645,149 in 2024 to $5,319,352 in 2025 and net income decreased from $1,881,667 ($0.41 per share) to $1,187,721 ($0.26 per share).

UG's Q1 earnings drop 39% as cosmetic sales plunge, offsetting gains in pharmaceuticals and medical lubricants.

UG's 2024 sales grow 12% y/y and earnings rise. Yet. the stock falls amid supply challenges and muted guidance, sparking mixed investor sentiment.